Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label Phase I, Dose Escalation Study of the Safety and Tolerability of OPD5 as Myeloablative Conditioning Regimen Followed by Autologous Stem Cell Transplant (ASCT) for Patients With Relapsed Refractory Multiple Myeloma (RRMM)

Next Previous
X
Search
Trial Profile

An Open-label Phase I, Dose Escalation Study of the Safety and Tolerability of OPD5 as Myeloablative Conditioning Regimen Followed by Autologous Stem Cell Transplant (ASCT) for Patients With Relapsed Refractory Multiple Myeloma (RRMM)

Status: Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 02 Dec 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs OPD 5 (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Acronyms COAST
  • Sponsors Oncopeptides

    • Most Recent Events

    • 17 Nov 2021 Status changed from suspended to withdrawn prior to enrolment. Sponsor made the decision to terminate the COAST study to refocus the OPD5 clinical program.
    • 09 Jul 2021 Status changed from recruiting to suspended (The study has been temporarily suspended while awaiting further analysis of data from othertrials).
    • 04 Jun 2021 Status changed from planning to recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top